HER2 Negative Breast Cancer
Symptoms, Doctors, Treatments, Advances & More

HER2 Negative Breast Cancer Overview

Save information for later
Sign Up

Learn About HER2 Negative Breast Cancer

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top HER2 Negative Breast Cancer Local Doctors?
Elite in HER2 Negative Breast Cancer
Elite in HER2 Negative Breast Cancer
Referral may be required

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Languages Spoken:
English
Offers Telehealth

Kevin Kalinsky is an Oncologist practicing medicine in Atlanta, Georgia. Dr. Kalinsky is rated as an Elite provider by MediFind in the treatment of HER2 Negative Breast Cancer. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Inflammatory Breast Cancer.

Elite in HER2 Negative Breast Cancer
Elite in HER2 Negative Breast Cancer
Referral may be required

Brigham And Women's Hospital, Division Of Breast Surgery

75 Francis Street, 
Boston, MA 
Languages Spoken:
English
Offers Telehealth

Dr. Lin is a medical oncologist specializing in the care of patients with all stages of breast cancer. Her research focuses upon improving the outcomes of people living with metastatic breast cancer, including a particular focus on the challenge of breast cancer brain metastases. She has led multiple clinical trials which have led to new treatment options for patients with breast cancer that has metastasized to the brain. Dr. Lin received her MD from Harvard Medical School in 1999. She completed her residency in internal medicine at Brigham and Women's Hospital and went on to complete fellowships in medical oncology and hematology at Dana-Farber. In 2005, she joined the staff of Brigham and Women's and Dana-Farber, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Dr. Lin is rated as an Elite provider by MediFind in the treatment of HER2 Negative Breast Cancer. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Brain Tumor, and Inflammatory Breast Cancer. Dr. Lin is board certified in Medical Oncology.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in HER2 Negative Breast Cancer
Elite in HER2 Negative Breast Cancer
Referral may be required
Ernst Grube Str. 40, 
Halle, NI, DE 

Christoph Thomssen practices practicing medicine in Halle, Germany. Mr. Thomssen is rated as an Elite expert by MediFind in the treatment of HER2 Negative Breast Cancer. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses HER2 Negative Breast Cancer, Breast Cancer, BRCA Positive Breast Cancer, Mastectomy, and Hormone Replacement Therapy (HRT).

What are the latest HER2 Negative Breast Cancer Clinical Trials?
Phase 1 Pilot Study With Dose Expansion of Chemotherapy in Combination With CD40 Agonist and Flt3 Ligand in Metastatic HER2 Negative Breast Cancer

Summary: This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, and to determine a safe dose and treatment...

Match to trials
Find the right clinical trials for you in under a minute
Get started
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic ER+, HER2- Breast Cancer

Summary: IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in partici...